Literature DB >> 21729518

Can RoTEM® analysis be applied for haemostatic monitoring in paediatric congenital heart surgery?

Jo Bønding Andreasen1, Anne-Mette Hvas, Kirsten Christiansen, Hanne Berg Ravn.   

Abstract

BACKGROUND: Successful management of bleeding disorders after congenital heart surgery requires detection of specific coagulation disturbances. Whole-blood rotation thromboelastometry (RoTEM®) provides continuous qualitative haemostatic profiles, and the technique has shown promising results in adult cardiac surgery.
SETTING: To compare the performance of RoTEM® with that of conventional coagulation tests in children, we conducted a descriptive study in children undergoing congenital cardiac surgery. For that purpose, 60 children were enrolled and had blood samples taken before, immediately after, and 1 day after surgery. Conventional coagulation tests included: activated partial thromboplastin time, prothrombin time, fibrinogen, fibrin D-dimer, thrombin clotting time, factor XIII, and platelet count.
RESULTS: Post-surgical haemostatic impairment was present to some degree in all children, as seen by pronounced changes in activated partial thromboplastin time, prothrombin time, thrombin clotting time, and platelet count, as well as RoTEM® analysis. RoTEM® showed marked changes in clotting time - prolonged by 7-18% - clot formation time - prolonged by 46-71% - maximum clot firmness - reduced by 10-19%, and maximum velocity - reduced by 29-39%. Comparison of the two techniques showed that conventional coagulation tests and RoTEM® performed equally well with regard to negative predictive values for excessive post-operative drain production - more than 20 millilitres per kilogram per 24 hours after surgery - with an area under the curve of approximately 0.65.
CONCLUSION: RoTEM® can detect haemostatic impairments in children undergoing cardiac surgery and the method should be considered as a supplement in the perioperative care of the children where targeted transfusion therapy is necessary to avoid volume overload.

Entities:  

Mesh:

Year:  2011        PMID: 21729518     DOI: 10.1017/S1047951111000758

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  5 in total

1.  Thromboelastometry during intraoperative transfusion of fresh frozen plasma in pediatric neurosurgery.

Authors:  Teemu Luostarinen; Marja Silvasti-Lundell; Tatjana Medeiros; Rossana Romani; Juha Hernesniemi; Tomi Niemi
Journal:  J Anesth       Date:  2012-05-06       Impact factor: 2.078

2.  Plasma and Platelet Transfusions Strategies in Neonates and Children Undergoing Cardiac Surgery With Cardiopulmonary Bypass or Neonates and Children Supported by Extracorporeal Membrane Oxygenation: From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.

Authors:  Jill M Cholette; Jennifer A Muszynski; Juan C Ibla; Sitaram Emani; Marie E Steiner; Adam M Vogel; Robert I Parker; Marianne E Nellis; Melania M Bembea
Journal:  Pediatr Crit Care Med       Date:  2022-01-01       Impact factor: 3.971

Review 3.  Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding.

Authors:  Anne Wikkelsø; Jørn Wetterslev; Ann Merete Møller; Arash Afshari
Journal:  Cochrane Database Syst Rev       Date:  2016-08-22

4.  Correlation Between ROTEM FIBTEM Maximum Clot Firmness and Fibrinogen Levels in Pediatric Cardiac Surgery Patients.

Authors:  Christopher F Tirotta; Richard G Lagueruela; Danielle Madril; Daria Salyakina; Weize Wang; Thomas Taylor; Jorge Ojito; Kathleen Kubes; Hyunsoo Lim; Robert Hannan; Redmond Burke
Journal:  Clin Appl Thromb Hemost       Date:  2018-12-05       Impact factor: 2.389

5.  The Use of Hemostatic Blood Products in Children Following Cardiopulmonary Bypass and Associated Outcomes.

Authors:  Ryan Closson; Elizabeth Mauer; Arabela Stock; Jeffrey D Dayton; Damien J LaPar; Maria C Walline; Marianne E Nellis
Journal:  Crit Care Explor       Date:  2020-08-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.